Ftse Mib
34.492,41
0,13%
DAX
18.497,94
-0,09%
S&P 500
5.277,51
0,80%
NASDAQ
16.735,02
-0,01%
Bitcoin
67.609,33
0,19%
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Orchard Therapeutics PLC (ORTX) Orchard Therapeutics PLC (ORTX) Notizie

ORTX

Orchard Therapeutics (ORTX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ORTX
DataOraFonteTitoloSimboloCompagnia
07/05/202413:00GlobeNewswire Inc.Orchard Therapeutics Announces Multiple Presentations at ASGCT 2024NASDAQ:ORTXOrchard Therapeutics PLC
03/05/202413:00GlobeNewswire Inc.Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024 TIME100 Health ListNASDAQ:ORTXOrchard Therapeutics PLC
20/03/202412:00GlobeNewswire Inc.Orchard Therapeutics Outlines U.S. Launch Plans for Lenmeldy™ (atidarsagene autotemcel), the Only Approved Therapy for Children with Early-onset Metachromatic LeukodystrophyNASDAQ:ORTXOrchard Therapeutics PLC
18/03/202420:41GlobeNewswire Inc.Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel), the Only Therapy for Eligible Children with Early-onset Metachromatic Leukodystrophy in the U.S.NASDAQ:ORTXOrchard Therapeutics PLC
15/02/202403:05Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ORTXOrchard Therapeutics PLC
05/02/202420:39Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:ORTXOrchard Therapeutics PLC
05/02/202413:00GlobeNewswire Inc.Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler SyndromeNASDAQ:ORTXOrchard Therapeutics PLC
02/02/202413:00GlobeNewswire Inc.Orchard Therapeutics Announces Multiple Presentations at the 20th Annual WORLDSymposiumNASDAQ:ORTXOrchard Therapeutics PLC
31/01/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ORTXOrchard Therapeutics PLC
25/01/202413:00GlobeNewswire Inc.Orchard Therapeutics Announces Agreement with the Beneluxa Consortium Enabling Reimbursed Access to LibmeldyNASDAQ:ORTXOrchard Therapeutics PLC
24/01/202423:20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ORTXOrchard Therapeutics PLC
24/01/202422:41Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:ORTXOrchard Therapeutics PLC
24/01/202422:28Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:ORTXOrchard Therapeutics PLC
24/01/202422:17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ORTXOrchard Therapeutics PLC
24/01/202411:00GlobeNewswire Inc.Kyowa Kirin successfully completes acquisition of Orchard Therapeutics, a global gene therapy leader for rare diseasesNASDAQ:ORTXOrchard Therapeutics PLC
11/12/202313:00GlobeNewswire Inc.Orchard Therapeutics Receives Swissmedic Approval for Libmeldy in Early-onset MLDNASDAQ:ORTXOrchard Therapeutics PLC
08/12/202322:39Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ORTXOrchard Therapeutics PLC
30/11/202313:00GlobeNewswire Inc.Orchard Therapeutics Receives U.S. FDA Fast Track Designation for OTL-203 in MPS-IHNASDAQ:ORTXOrchard Therapeutics PLC
16/11/202322:45Edgar (US Regulatory)Form DEFM14A - Definitive proxy statement relating to merger or acquisitionNASDAQ:ORTXOrchard Therapeutics PLC
13/11/202313:10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ORTXOrchard Therapeutics PLC
13/11/202313:00GlobeNewswire Inc.Orchard Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Business AccomplishmentsNASDAQ:ORTXOrchard Therapeutics PLC
03/11/202322:11Edgar (US Regulatory)Form PREM14A - Preliminary proxy statements relating to merger or acquisitionNASDAQ:ORTXOrchard Therapeutics PLC
26/10/202313:00GlobeNewswire Inc.Orchard Therapeutics Announces Presentation of Additional Positive Data from Proof-of-concept Study of OTL-203 in MPS-IH at ESGCT 2023NASDAQ:ORTXOrchard Therapeutics PLC
24/10/202313:00GlobeNewswire Inc.Orchard Therapeutics Announces Multiple Presentations at ESGCT 2023NASDAQ:ORTXOrchard Therapeutics PLC
05/10/202323:26Edgar (US Regulatory)Form DEFA14C - Additional information statement materials, definitiveNASDAQ:ORTXOrchard Therapeutics PLC
05/10/202313:19IH Market NewsThursday’s Wall Street Highlights: Orchard Therapeutics, Exxon Mobil, Alphabet, Ford, and moreNASDAQ:ORTXOrchard Therapeutics PLC
05/10/202309:35GlobeNewswire Inc.Kyowa Kirin to Acquire Orchard TherapeuticsNASDAQ:ORTXOrchard Therapeutics PLC
18/09/202313:00GlobeNewswire Inc.Orchard Therapeutics Announces Acceptance of Biologics License Application for OTL-200 in MLD and Receives Priority ReviewNASDAQ:ORTXOrchard Therapeutics PLC
31/08/202313:00GlobeNewswire Inc.Orchard Therapeutics Announces Presentation of Data Comprising the Clinical Package for the OTL-200 BLA in MLD at the SSIEM Annual Symposium 2023NASDAQ:ORTXOrchard Therapeutics PLC
21/08/202322:32Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ORTXOrchard Therapeutics PLC
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ORTX

La tua Cronologia

BIT
UCG
Unicredit
BIT
TIT
Telecom Italia
BIT
ISP
Intesa Sanpaolo
BIT
STLAM
Stellantis NV
BIT
STMMI
ST Microelectronics
BIT
ENI
Eni
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
TITR
Telecom Italia
BIT
ENEL
Enel
BIT
TEN
Tenaris
BIT
BPE
Bper Banca
BIT
RACE
Ferrari NV
BIT
LDO
Leonardo
BIT
PIRC
Pirelli & C
BIT
SPM
Saipem
BIT
MONC
Moncler
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network